Stock analysts at Lifesci Capital cut their FY2025 earnings per share estimates for Astria Therapeutics in a research report ...
LifeSci Capital analyst Charles Zhu initiated coverage with a Buy rating on Zymeworks (ZYME – Research Report) today and set a price target of ...
Investment analysts at Lifesci Capital issued their Q1 2025 EPS estimates for Protara Therapeutics in a note issued to ...
Fintel on MSN7d
LifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationFintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Molecular Partners AG - Depositary Receipt () ...
In a report released today, Charles Zhu from LifeSci Capital initiated coverage with a Buy rating on Molecular Partners (MOLN – Research ...
Fintel reports that on March 11, 2025, LifeSci Capital initiated coverage of Protara Therapeutics (NasdaqGM:TARA) with a Outperform recommendation. As of March 4, 2025, the average one-year price ...
Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. As of March 4, 2025, the average one-year ...
In addition to LifeSci Capital, Zymeworks also received a Buy from J.P. Morgan’s Brian Cheng in a report issued on March 6. However, on March 7, H.C. Wainwright reiterated a Hold rating on ...
The Fund seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Products Index. The Index seeks to track the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback